- Home
- UUU vs BRNS Comparison
UUU vs BRNS Comparison
Compare UUU & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UUU | BRNS |
|---|---|---|
| Founded | 1969 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.4M | 24.1M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | UUU | BRNS |
|---|---|---|
| Price | $4.11 | $0.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 20.4K | ★ 38.6K |
| Earning Date | 02-19-2026 | 05-07-2026 |
| Dividend Yield | ★ 16.75% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,847,163.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.86 | $0.51 |
| 52 Week High | $8.27 | $2.91 |
Technical Indicators
Market Signals| Indicator | UUU | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 30.07 | 44.89 |
| Support Level | N/A | $0.56 |
| Resistance Level | $6.25 | $0.75 |
| Average True Range (ATR) | 0.31 | 0.05 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 17.30 | 27.25 |
Price Performance
Historical ComparisonAbout UUU Universal Security Instruments Inc.
Universal Safety Products Inc is a U.S.-based importer and distributor of home safety devices such as ventilation fans and ground fault circuit interrupters.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.